Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
2014
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Molecular imaging of hypoxia with radiolabelled agents
2009
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Second-line treatment for primary central nervous system lymphoma
1999
Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients
2016
Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors
2003
Targeting hypoxia in cancer therapy
2011 Standout
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
2018
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
2010
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
The cerebellum and cognition
2018 Standout
Measurement of brain perfusion, blood volume, and blood‐brain barrier permeability, using dynamic contrast‐enhanced T1‐weighted MRI at 3 tesla
2009
Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.
1996
Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis
2010
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Therapeutic apheresis in neurological disorders
2000
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Primary intracerebral malignant lymphoma: report of 248 cases
2000
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report
2005
Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
1999
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
2010
Skeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
2007
Glioblastoma and Other Malignant Gliomas
2013 Standout
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Primary CNS Lymphoma: Findings Outside the Brain
1999
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Medical management of brain tumors and the sequelae of treatment
2014
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
2011
Causes and Consequences of Increased Glucose Metabolism of Cancers
2008
Primary CNS Lymphoma: Treatment with Combined Chemotherapy and Radiotherapy
1999
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome
2001
Antiangiogenic therapy in malignant gliomas
2008
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas
2004
Immunoadsorption therapy for paraneoplastic syndromes
1998
Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen
2013
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Epigenetics in Cancer
2008 Standout
Tumor treating fields: a novel treatment modality and its use in brain tumors
2016
Long-term survival in primary CNS lymphoma.
1998
Regulation of cancer cell metabolism
2011 Standout
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
2007 Standout
Radiotherapy in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)
1999
Quantitative imaging biomarkers in neuro-oncology
2009
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity
1998
Malignant Gliomas in Adults
2008 Standout
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions
2016
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
2019
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Primary brain tumours in adults
2003
Blood-Brain Barrier Breakdown in the Aging Human Hippocampus
2015 Standout
Primary brain tumours in adults
2012 Standout
Functional topography in the human cerebellum: A meta-analysis of neuroimaging studies
2008 Standout
Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood–tumor and blood–brain barriers improve outcomes in a rat glioma model
2013
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
2008
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
2015
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection
2015
Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.
1997
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.
1998
Reactive oxygen species-driven HIF1α triggers accelerated glycolysis in endothelial cells exposed to low oxygen tension
2016
Antiangiogenic therapies for high-grade glioma
2009
Targeting TGF-β Signaling in Cancer
2017
CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma
2001
Phase II Trial of Pre-irradiation KRN8602 (MX2) in Malignant Glioma Patients
2000
The cerebellar cognitive affective syndrome
1998 Standout
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
2017
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
High-dose methotrexate for elderly patients with primary CNS lymphoma
2008
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Novel anti-angiogenic therapies for malignant gliomas
2008
Brain Tumors
2001 Standout
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients
2000 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of Patients
1999
Clinical Applications of PET in Brain Tumors
2007
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Antibody-Mediated Encephalitis
2018 Standout
Primary CNS Lymphoma in Immunocompetent Patients
2009
Opsoclonus myoclonus syndrome: response to plasmapheresis.
2004
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
Anti-angiogenic therapy for high-grade glioma
2018
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
2004 Standout
Angiogenesis as a Therapeutic Target in Malignant Gliomas
2009
Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?
1997
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
2006
Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments
2002
Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96–07
2003
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
2006
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
2013
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
2009
In Vivo Photoacoustic Tomography of Chemicals: High-Resolution Functional and Molecular Optical Imaging at New Depths
2010
Clinical outcome of patients with anti-Hu–associated encephalomyelitis after treatment of the tumor
1999
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
Treatment for Primary CNS Lymphoma: The Next Step
2000
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma
2000
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Cortical cerebellar degeneration with testicular neoplasm
1985
Diagnosis and management of vertebral artery stenosis
2003
The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]
1995
Works of Lawrence Cher being referenced
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
2010
Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma
2017
Therapy for paraneoplastic neurologic syndromes in six patients with protein a column immunoadsorption
1995
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide
2004
Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome
1994
High-dose methotrexate for primary CNS lymphoma in the elderly
2000
Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)
1996
Phase 2 study of temozolomide and Caelyx in patients with recurrentglioblastoma multiforme
2004
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
2016
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy
2011
Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy
1996
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
2015
High-dose methotrexate for primary CNS lymphoma in the elderly
2000
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
2013
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
2006
Comparison of transcranial Doppler with DSA in vertebrobasilar ischaemia.
1992
Cancer and the nervous system
2001
KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma
1999
Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study
2008
Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting.
1996
Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.
2013